ENDRA Life Sciences Inc. (NASDAQ: NDRA)
$5.5400
-2.1300 ( -27.80% ) 234.9K
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Market Data
Open
$5.5400
Previous close
$7.6720
Volume
234.9K
Market cap
$3.03M
Day range
$0.7790 - $7.5950
52 week range
$0.7790 - $4,882.5000
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 17 | Aug 16, 2024 |
3 | Insider transactions | 2 | Aug 15, 2024 |
10-q | Quarterly Reports | 61 | Aug 14, 2024 |
8-k | 8K-related | 16 | Aug 13, 2024 |
8-k | 8K-related | 16 | Aug 09, 2024 |
8-k | 8K-related | 15 | Jul 17, 2024 |
ars | Annual reports | 76 | Jun 25, 2024 |
def | Proxies and info statements | 9 | Jun 25, 2024 |
pre | Proxies and info statements | 9 | Jun 12, 2024 |
8-k | 8K-related | 16 | Jun 06, 2024 |